Effects of high-dose modified-release nicotinic Acid on atherosclerosis and vascular function a randomized, placebo-controlled, magnetic resonance imaging study.
Lee et al.
J Am Coll Cardiol 2009;54:1787-1794.
ABSTRACT
| FULL TEXT
Dyslipidemia and cardiovascular risk: the importance of early prevention
Miller
QJM 2009;102:657-667.
ABSTRACT
| FULL TEXT
Is There Evidence-based Hypolipidemic Treatment With Clinical Benefit Beyond Statins?
Goumas
ANGIOLOGY 2009;60:93-98.
ABSTRACT
Standards of Medical Care in Diabetes--2009
American Diabetes Association
Diabetes Care 2009;32:S13-S61.
FULL TEXT
CHAPTER 14 Diabetes Mellitus and Metabolic Syndrome
Cosentino et al.
ESC Textbook of Cardiovascular Medicine 2009;2:med-9780199566990-chapter-med-9780199566990-chapter.
ABSTRACT
| FULL TEXT
The Metabolic Syndrome
Cornier et al.
Endocr. Rev. 2008;29:777-822.
ABSTRACT
| FULL TEXT
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients
Fruchart et al.
Diabetes and Vascular Disease Research 2008;5:319-335.
ABSTRACT
Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels
Hausenloy and Yellon
Postgrad. Med. J. 2008;84:590-598.
ABSTRACT
| FULL TEXT
Adipokines--targeting a root cause of cardiometabolic risk
Bakhai
QJM 2008;101:767-776.
ABSTRACT
| FULL TEXT
A Practical 'ABCDE' Approach to the Metabolic Syndrome
Blaha et al.
Mayo Clin Proc. 2008;83:932-943.
ABSTRACT
| FULL TEXT
Postprandial triglyceride responses to aerobic exercise and extended-release niacin
Plaisance et al.
Am. J. Clin. Nutr. 2008;88:30-37.
ABSTRACT
| FULL TEXT
Overproduction of Very Low-Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome
Adiels et al.
Arterioscler. Thromb. Vasc. Bio. 2008;28:1225-1236.
ABSTRACT
| FULL TEXT
Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes
Triplitt and Alvarez
Diabetes Spectr. 2008;21:177-189.
ABSTRACT
| FULL TEXT
Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels
Hausenloy and Yellon
Heart 2008;94:706-714.
ABSTRACT
| FULL TEXT
Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus Conference Report From the American Diabetes Association and the American College of Cardiology Foundation
Brunzell et al.
J Am Coll Cardiol 2008;51:1512-1524.
FULL TEXT
Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation
Brunzell et al.
Diabetes Care 2008;31:811-822.
FULL TEXT
Effects of Niacin on Glucose Control in Patients With Dyslipidemia
Goldberg and Jacobson
Mayo Clin Proc. 2008;83:470-478.
ABSTRACT
| FULL TEXT
Effects of Antidiabetic and Antihyperlipidemic Agents on C-Reactive Protein
Dandona
Mayo Clin Proc. 2008;83:333-342.
ABSTRACT
| FULL TEXT
Lipid Management to Reduce Cardiovascular Risk: A New Strategy Is Required
Superko and King
Circulation 2008;117:560-568.
FULL TEXT
Standards of Medical Care in Diabetes--2008
American Diabetes Association
Diabetes Care 2008;31:S12-S54.
FULL TEXT
Niacin Lowers Serum Phosphate and Increases HDL Cholesterol in Dialysis Patients
Muller et al.
CJASN 2007;2:1249-1254.
ABSTRACT
| FULL TEXT
Hypertriglyceridemia
Brunzell
NEJM 2007;357:1009-1017.
FULL TEXT
High-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh et al.
JAMA 2007;298:786-798.
ABSTRACT
| FULL TEXT
Raising HDL Cholesterol in Patients With Diabetes
DOC News 2007;4:4-4.
FULL TEXT
The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease
Windler et al.
Diabetes and Vascular Disease Research 2007;4:136-142.
ABSTRACT
Low-Density Lipoprotein-Dependent and -Independent Effects of Cholesterol-Lowering Therapies on C-Reactive Protein: A Meta-Analysis
Kinlay
J Am Coll Cardiol 2007;49:2003-2009.
ABSTRACT
| FULL TEXT
Antilipolytic Activity of a Novel Partial A1 Adenosine Receptor Agonist Devoid of Cardiovascular Effects: Comparison with Nicotinic Acid
Dhalla et al.
J. Pharmacol. Exp. Ther. 2007;321:327-333.
ABSTRACT
| FULL TEXT
Rational therapy of mixed dyslipidaemia in a patient with diabetes
Reasner
British Journal of Diabetes & Vascular Disease 2007;7:25-30.
ABSTRACT
Standards of Medical Care in Diabetes--2007
American Diabetes Association
Diabetes Care 2007;30:S4-S41.
FULL TEXT
Transcriptome of the subcutaneous adipose tissue in response to oral supplementation of type 2 Leprdb obese diabetic mice with niacin-bound chromium
Rink et al.
Physiol. Genomics 2006;27:370-379.
ABSTRACT
| FULL TEXT
Improved Triglycerides and Insulin Sensitivity with 3 Months of Acipimox in Human Immunodeficiency Virus-infected Patients with Hypertriglyceridemia
Hadigan et al.
J. Clin. Endocrinol. Metab. 2006;91:4438-4444.
ABSTRACT
| FULL TEXT
Diabetic dyslipidaemia: the triad
Wierzbicki
Eur Heart J Suppl 2006;8:F30-F33.
ABSTRACT
| FULL TEXT
Achieving the therapeutic benefits of Niaspan(R) in daily practice
Reasner
Eur Heart J Suppl 2006;8:F68-F73.
ABSTRACT
| FULL TEXT
NAUTILUS (Safety and tolerability of Niaspan(R)): a subgroup analysis in patients with diabetes
Vogt et al.
British Journal of Diabetes & Vascular Disease 2006;6:127-133.
ABSTRACT
Management of Dyslipidemia in Special Populations
Tovar and Schering
Journal of Pharmacy Practice 2006;19:63-78.
ABSTRACT
Additional Information
JAMA 2006;295:E7-E14.
FULL TEXT
REVIEW: Efficacy and Mechanisms of Action of Statins in the Treatment of Diabetic Dyslipidemia
Ginsberg
J. Clin. Endocrinol. Metab. 2006;91:383-392.
ABSTRACT
| FULL TEXT
Standards of Medical Care in Diabetes-2006
American Diabetes Association
Diabetes Care 2006;29:S4-S42.
FULL TEXT
Managing Abnormal Blood Lipids: A Collaborative Approach
Fletcher et al.
Circulation 2005;112:3184-3209.
ABSTRACT
| FULL TEXT
Review: Treatment of lipids to reduce cardiovascular risk among people with the metabolic syndrome or type 2 diabetes
Wild and Byrne
British Journal of Diabetes & Vascular Disease 2005;5:315-319.
ABSTRACT
Reducing cardiovascular risk in patients with type 2 diabetes: the potential contribution of nicotinic acid
Van Gaal et al.
British Journal of Diabetes & Vascular Disease 2005;5:344-350.
ABSTRACT
Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
Grundy et al.
Circulation 2005;112:2735-2752.
FULL TEXT
The importance of low serum levels of high-density lipoprotein cholesterol (HDL-C) as a cardiovascular risk factor
Espinosa-Larranaga et al.
Diabetes and Vascular Disease Research 2005;2:S1-S8.
ABSTRACT
Inflammation, Atherosclerosis, and Aspects of Insulin Action
Bloomgarden
Diabetes Care 2005;28:2312-2319.
FULL TEXT
Niaspan(R): creating a new concept for raising HDL-cholesterol
McGovern
Eur Heart J Suppl 2005;7:F41-F47.
ABSTRACT
| FULL TEXT
Niaspan(R): a powerful treatment option for 'diabetic dyslipidaemia'
Reasner
Eur Heart J Suppl 2005;7:F48-F55.
ABSTRACT
| FULL TEXT
Dyslipidaemia among Indo-Asians strategies for identification and management
Enas et al.
British Journal of Diabetes & Vascular Disease 2005;5:81-90.
ABSTRACT
Role of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: an Asian/Pacific consensus: The Pan-Asian Consensus Panel On Hdl-C
Barter
British Journal of Diabetes & Vascular Disease 2005;5:S1-S15.
ABSTRACT
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A meta-analysis of randomized controlled trials
Birjmohun et al.
J Am Coll Cardiol 2005;45:185-197.
ABSTRACT
| FULL TEXT
A Randomized Trial of a Strategy for Increasing High-Density Lipoprotein Cholesterol Levels: Effects on Progression of Coronary Heart Disease and Clinical Events
Whitney et al.
ANN INTERN MED 2005;142:95-104.
ABSTRACT
| FULL TEXT
Modern intervention strategies for managing dyslipidaemia: the case for combination therapy
Drexel
British Journal of Diabetes & Vascular Disease 2005;5:S17-S23.
ABSTRACT
Standards of Medical Care in Diabetes
American Diabetes Association
Diabetes Care 2005;28:S4-S36.
FULL TEXT
Atherosclerosis Imaging and the Future of Lipid Management
Grundy
Circulation 2004;110:3509-3511.
FULL TEXT
Abdominal Obesity and Dyslipidemia in the Metabolic Syndrome: Importance of Type 2 Diabetes and Familial Combined Hyperlipidemia in Coronary Artery Disease Risk
Carr and Brunzell
J. Clin. Endocrinol. Metab. 2004;89:2601-2607.
ABSTRACT
| FULL TEXT
Lipids and Lipoproteins in Patients With Type 2 Diabetes
Krauss
Diabetes Care 2004;27:1496-1504.
ABSTRACT
| FULL TEXT
Low Maternal Dietary Intakes of Iron, Magnesium, and Niacin Are Associated with Spina Bifida in the Offspring
Groenen et al.
J. Nutr. 2004;134:1516-1522.
ABSTRACT
| FULL TEXT
New Perspectives on the Use of Niacin in the Treatment of Lipid Disorders
McKenney
Arch Intern Med 2004;164:697-705.
ABSTRACT
| FULL TEXT
Clinical Trials and Lipid Guidelines for Type II Diabetes
Prisant
J Clin Pharmacol 2004;44:423-430.
ABSTRACT
| FULL TEXT
Reduction in C-reactive protein through cardiac rehabilitation and exercise training
Milani et al.
J Am Coll Cardiol 2004;43:1056-1061.
ABSTRACT
| FULL TEXT
Review: Use of nicotinic acid in patients with elevated fasting glucose, diabetes, or metabolic syndrome
Mcgovern
British Journal of Diabetes & Vascular Disease 2004;4:78-85.
ABSTRACT
The Metabolic Syndrome: Pathophysiology, Clinical Relevance, and Use of Niacin
Ito
The Annals of Pharmacotherapy 2004;38:277-285.
ABSTRACT
| FULL TEXT
Role of C-Reactive Protein in Cardiovascular Disease
Backes et al.
The Annals of Pharmacotherapy 2004;38:110-118.
ABSTRACT
| FULL TEXT
Standards of Medical Care in Diabetes
Diabetes Care 2004;27:s15-35.
FULL TEXT
Varying Cost and Free Nicotinic Acid Content in Over-the-Counter Niacin Preparations for Dyslipidemia
Meyers et al.
ANN INTERN MED 2003;139:996-1002.
ABSTRACT
| FULL TEXT
Inflammation, Hypertension, and the Metabolic Syndrome
Grundy
JAMA 2003;290:3000-3002.
FULL TEXT
Diabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part II
Luscher et al.
Circulation 2003;108:1655-1661.
FULL TEXT
Medical Management of Hyperlipidemia/Dyslipidemia
Kreisberg and Oberman
J. Clin. Endocrinol. Metab. 2003;88:2445-2461.
FULL TEXT
Niacin as a Component of Combination Therapy for Dyslipidemia
Miller
Mayo Clin Proc. 2003;78:735-742.
ABSTRACT
The Use of Niacin in Diabetes Mellitus
Mikhail
Arch Intern Med 2003;163:369-369.
FULL TEXT
OTHER ARTICLES NOTED (Nov 01 to 18 Oct 02)
Evid. Based Nurs. 2003;6:e1-1.
FULL TEXT
Niacin-ER and Lovastatin Treatment of Hypercholesterolemia and Mixed Dyslipidemia
Yim and Chong
The Annals of Pharmacotherapy 2003;37:106-115.
ABSTRACT
| FULL TEXT
Standards of Medical Care for Patients With Diabetes Mellitus
Diabetes Care 2003;26:S33-S50.
FULL TEXT
Combination therapy: its rationale and the role of ezetimibe
Stone
Eur Heart J Suppl 2002;4:J19-J22.
ABSTRACT